Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968760 | 0.83 | L3MBTL1 (0.41) | KDM4EHDAC1KMT2AMEN1HDAC8 | |
| SCHEMBL9931328 | 0.79 | KDM4E (0.49) | KDM4EHDAC1KMT2AHDAC8HTT | |
| SCHEMBL10298786 | 0.78 | HDAC1 (0.54) | KDM4EHDAC1KMT2AMEN1HDAC8 | |
| SCHEMBL27866535 | 0.75 | JAK2 (0.46) | KDM4EHDAC1HDAC8HTTPPARG | |
| SCHEMBL421355 | 0.74 | GNRHR (0.48) | HDAC1HDAC8PPARGSMN1; SMN2TP53 | |
| SCHEMBL6893748 | 0.73 | HDAC1 (0.43) | HDAC1HDAC8TBXA2R | |
| SCHEMBL10298662 | 0.72 | KCNH2 (0.44) | KDM4EHDAC1KMT2AHTTTP53 | |
| SCHEMBL16176599 | 0.71 | PPARG (0.43) | HDAC1HDAC8HTTPPARGTP53 | |
| SCHEMBL27885535 | 0.71 | KDM4E (0.47) | KDM4EHDAC1KMT2AHDAC8HTT | |
| SCHEMBL12636229 | 0.71 | HDAC6 (0.45) | KDM4EHDAC1HTTTBXA2RPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993765-B2 | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| WO-2012088124-A2 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | MCHR1, MCHR2, MC5R | KDM4E 630/4885HDAC1 1363/4885KMT2A 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.